Clonidine for ADHD
Clonidine is an alpha-2 agonist.
Trade names of clonidine are:
- Catapresan (A, D, CH)
- Haemiton (D)
- Isoglaucon (A, D)
- Paracefan (D)
- Kapvay (USA; prolonged-release clonidine hydrochloride)
- Onyda XR (USA; prolonged-release clonidine hydrochloride)
Clonidine is available in immediate release and sustained release.
Sustained release clonidine is approved by the FDA for the treatment of ADHD for children 6 years of age and older.1 Two doses per day are required for all-day coverage.
Immediate release clonidine is used off-label for people with ADHD who have difficulty swallowing tablets. Immediate release clonidine must be taken 4 to 4 times a day.
Clonidine is a rather atypical medication for ADHD.
Effect sizes in relation to ADHD:
- 0.71 for children and adolescents2, which seems to us to be too high and due to an insufficient number of studies3
- 0.03 (meta-analysis)4
Clonidine is commonly used for autism spectrum disorders and may be helpful for comorbid ASD + ADHD in young children.5
There are 12 evidence-based guidelines on the use of clonidine at6
- High blood pressure: 1
- Substance abuse: 4
- Menopause: 4
- Restless legs: 2
- Tourette: 1
- ADHD: none
- Migraine prophylaxis: none
1. Mechanisms of action of clonidine
Clonidine acts in the PFC7 as:
- Σ-2A-adrenoreceptor agonist87
- Σ-2B-adrenoreceptor agonist87
- Σ-2C-adrenoreceptor agonist87
- Imidazoline receptor agonist
- Σ-1-adrenoceptor agonist with too fast, too high dosage (injected)9
Clonidine weakens the effect of adrenaline.
Alpha-2-adrenoceptors are activated endogenously by the neurotransmitters adrenaline and noradrenaline. They are therefore responsible for the effects mediated by adrenaline and noradrenaline.10
Alpha-2-A receptor agonists such as clonidine and guanfacine are thought to enhance a phasic release of noradrenaline in the nucleus coeruleus, which improves attention as well as working memory and visuomotor-associated learning (as opposed to a long-term tonic release of noradrenaline, which impairs performance).11
Clonidine thus has a noradrenergic effect.
As an alpha-2-adrenoceptor agonist, clonidine (like guanfacine) significantly reduces the release of dopamine in the nucleus accumbens in the laboratory.12
Clonidine and guanfacine are said to be helpful for rejection sensitivity in ADHD.13
A 2019 study from India reported that clonidine was the most commonly used medication for ADHD in a group of children aged 3 to 6 years with ADHD:14
- Clonidine: 44.6 %
- Risperidone: 28.7 %
- Methylphenidate: 10.7 %
- Atomoxetine: 10.7 %
Clonidine worked better than methylphenidate with halperidol in children with ADHD and comorbid tic disorders.15
The optimum dosage for children and adolescents should be 0.9 mg / kg / day.16
2. Side effects
Clonidine has higher side effects than methylphenidate and atomoxetine.8
Side effects of clonidine are dose-dependent, in particular1
- Sedation*
- Daytime tiredness*
- Drop in blood pressure*
- Bradycardia and hypotension, especially with renal dysfunction
- Vascular damage and thrombosis, especially in older people with endothelial damage (damage to the inner layer of blood vessels)17
*These side effects may decrease after dosing.18
Dosing in and dosing out should be slow and gradual.1 To avoid rebound hypertension, it is recommended that clonidine be reduced every 3 to 7 days at a dose of 0.1 mg per day until it is discontinued.18
The sedative effect can also be used positively by administering higher doses before going to bed.1
Vilus JT, Engelhard C (2025): Nonstimulant Medications for Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatr Ann. 2025 Jan;54(1):e27-e33. doi: 10.3928/19382359-20241007-07. PMID: 39760346. REVIEW ↥ ↥ ↥ ↥
Cortese, Adamo, Del Giovane, Mohr-Jensen, Hayes, Carucci, Atkinson, Tessari, Banaschewski, Coghill, Hollis, Simonoff, Zuddas, Barbui, Purgato, Steinhausen, Shokraneh, Xia, Cipriani (2018): Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis; The Lancet Psychiatry, VOLUME 5, ISSUE 9, P727-738, SEPTEMBER 01, 2018; Open Access; DOI:https://doi.org/10.1016/S2215-0366(18)30269-4 METASTUDY ↥
Nageye, Cortese (2019): Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD. Expert Rev Neurother. 2019 Jul;19(7):707-717. doi: 10.1080/14737175.2019.1628640. PMID: 31167583.) ↥
Faraone SV (2009): Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths. P T. 2009 Dec;34(12):678-94. PMID: 20140141; PMCID: PMC2810184. METASTUDY ↥
Manohar, Kuppili, Kandasamy, Chandrasekaran, Rajkumar (2018): Implications of comorbid ADHD in ASD interventions and outcome: Results from a naturalistic follow up study from south India. Asian J Psychiatr. 2018 Mar 2;33:68-73. doi: 10.1016/j.ajp.2018.03.009., n = 50 ↥
Review of Guidelines on Clonidine for Various Indications: Rapid Review [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Aug (2024): Report No.: RC1543. PMID: 39312608. REVIEW ↥
Neuchat EE, Bocklud BE, Kingsley K, Barham WT, Luther PM, Ahmadzadeh S, Shekoohi S, Cornett EM, Kaye AD (2023): The Role of Alpha-2 Agonists for Attention Deficit Hyperactivity Disorder in Children: A Review. Neurol Int. 2023 May 22;15(2):697-707. doi: 10.3390/neurolint15020043. PMID: 37218982; PMCID: PMC10204383. REVIEW ↥ ↥ ↥ ↥
Guanfacin, Wirkstoff Aktuell, Ausgabe 2/2016, Stand 11.04.2015, Information der KBV ↥ ↥ ↥ ↥
Manz (2018): 05. Monoamine 2: Amphetamin, Ritalin (ADHS), Cocain, Tricyclika, Videovorlesung. ca. bei Minute 06:30. ↥
Steinhausen, Rothenberger, Döpfner (2010): Handbuch ADHS, Seiten 84, 85 ↥
Nurse, Russell, Taljaard (1985): Effect of chronic desipramine treatment on adrenoceptor modulation of [3H]dopamine release from rat nucleus accumbens slices. Brain Res. 1985 May 20;334(2):235-42 ↥
Dodson: How ADHD Ignites Rejection Sensitive Dysphoria; The extreme emotional pain of perceived rejection is a feeling unique to people with ADHD, and it can be debilitating. Learn how RSD may be impacting your patients; in: ADDitude. Strategies and Support für ADD & LD ↥
Vaidyanathan, Rajan, Chandrasekaran, Kandasamy (2019): Pre-school attention deficit hyperactivity disorder: 12 weeks prospective study. Asian J Psychiatr. 2019 Dec 14;48:101903. doi: 10.1016/j.ajp.2019.101903. n = 56 ↥
Zeng KD, Wang GL, Yuan Y, Zhang W, Huang XH, Hu B (2023): Efficacy of clonidine in the treatment of children with tic disorder co-morbid with attention deficit hyperactivity disorder. Eur Rev Med Pharmacol Sci. 2023 May;27(9):4232-4238. doi: 10.26355/eurrev_202305_32333. PMID: 37203849. ↥
Yellepeddi V, Bayless S, Parrot M, Sherwin CM (2024): Optimal Dosing Recommendations of Clonidine in Pediatrics Using Physiologically Based Pharmacokinetic Modeling. J Pediatr Pharmacol Ther. 2024 Dec;29(6):636-644. doi: 10.5863/1551-6776-29.6.636. PMID: 39659862; PMCID: PMC11627573. ↥
Manz (2018): 05. Monoamine 2: Amphetamin, Ritalin (ADHS), Cocain, Tricyclika, Videovorlesung. ↥
Jain R, Segal S, Kollins SH, Khayrallah M (2011): Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011 Feb;50(2):171-9. doi: 10.1016/j.jaac.2010.11.005. PMID: 21241954. ↥ ↥